ZEN Graphene Solutions Ltd.: ZEN Graphene Solutions Announces Successful Testing of Its Graphene Compound Against Antimicrobial-Resistant Bacteria
ZEN" or the "
Company") (TSXV:ZEN) and (OTCPINK:ZENYF), a next-gen nanomaterials technology company, is pleased to announce successful testing results of its patent-pending graphene-based compound against four gram-positive and nine gram-negative bacteria with antimicrobial-resistance (AMR), including multidrug-resistant variants like methicillin-resistant staphylococcus aureus (MRSA). Testing was completed under the direction of Dr. Tony Mazzulli, MD, FRCPC, FACP, Microbiologist-in-Chief and Infectious Disease Specialist at University Health Network/Mount Sinai Hospital, following initial breakthrough results demonstrating that the compound is 99.9% effective against viruses, bacteria, and fungi. With the goal of targeting pathogens in humans, the results are even more significant considering the extremely low minimum inhibitory concentration (MIC) and the excellent safety profile established during Nucro-Technics' seven-day repeated dose study reported in early March.